A new standard of diabetes care

Reduction of Both A1C and Hypoglycemia

Real-time continuous glucose monitoring (RT-CGM) is the only diabetes management tool proven to reduce A1C while decreasing time spent in hypoglycemia–and patients experience these benefits regardless of delivery method.1,2

Continuous Information for More Insight

Unlike a blood glucose meter, which provides just a single reading, RT-CGM provides continuous, dynamic real-time information about a user's glucose levels. With readings every five minutes – up to 288 readings a day – patients will know where their glucose is headed and how fast it's getting there.

Recognized by Professional Societies

Professional societies have broadened their recommendation of RT-CGM and its application in patient care protocols in adult and pediatric type 1 and type 2 diabetes patients, including those on insulin therapy as well as oral anti-diabetic agents (OAAs).

See CGM Positioning Statment

Dexcom CGM First™

Professional societies, including the ADA, AACE and the Endocrine Society now recognize RT-CGM as a standard of care.3-5 Dexcom CGM use has been proven to both reduce A1C and decrease risk of hypoglycemia regardless of insulin delivery method.2 Optimize your patients' diabetes treatment plans and prescribe a Dexcom CGM System today.

Limitations of SMBG

With SMBG, patients may be reluctant to test for a variety of reasons, including pain and discomfort, the hassles and lack of discretion.6

How Your Patients Can Benefit

RT-CGM use may benefit your newly diagnosed patient with type 1 diabetes or your patient who has been struggling to maintain control after living with type 2 diabetes for many years. CGM can benefit a broad profile of insulin-using patients, whether they are on multiple daily injections (MDI) insulin regimen or insulin therapy.


Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes, N Engl J Med. 2008: 359(14); 1464-1476.


Soupal J, Petruzelkova L, Flekac M, et al. Comparison of Different Treatment Modalities for Type 1 Diabetes, Including Sensor-Augmented Insulin Regimens, in 52 Weeks of Follow-Up: A COMISAIR Study. Diabetes Technol Ther. 2016;18(9):532-538.


American Diabetes Association. Glycemic Targets: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S55-S64.


Bailey TS, Grunberger G, Bode BW, et al. American Association of Clinical Endocrinologists and American College of Endocrinology 2016 Outpatient Glucose Monitoring Consensus Statement. Endocr Pract.



Peters AL, Ahmann AJ, Battelino T, et al. Diabetes Technology-Continuous Subcutaneous Insulin Infusion Therapy and Continuous Glucose Monitoring in Adults: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016:jc20162534.


Fisher WA, Kohut T, Schachner H, Stenger P. Understanding self-monitoring of blood glucose among individuals with type 1 and type 2 diabetes: an information-motivation-behavioral skills analysis. Diabetes Educ. 2011 Jan-Feb;37(1):85-94.

Contact Dexcom

If you are a clinician and want to learn more about Dexcom’s Continuous Glucose Monitoring Systems, please fill out the form and a Dexcom representative will contact you.

If you are a Dexcom User or Patient, please contact Dexcom here.

The information you provide will be sent securely and subject to the Dexcom Terms of Use and Privacy Policy.